Ingolimod to get a median of ten.3 months (range three.014) totaling 524.6 personyears with 163 postfingolimod initiation relapses reported for 111 sufferers.Table 1 summarizes demographic and baseline clinical traits of the three fingolimod patient groups. Sufferers who had been remedy naive at fingolimod get started had been younger than these switching from natalizumab (p five 0.003). Disease duration at treatment get started differed in between all patient groups (p , 0.0001 for all comparisons). Moreover, sufferers switching from natalizumab to fingolimod had a higher baseline EDSS (median four, IQR two) than those that were previously treatment naive (median 1.five, IQR 0; p , 0.0001), or switching from IFNb/GA (median two.five, IQR 1.five; p , 0.0001). There have been no statistically substantial variations in baseline EDSS scores amongst the treatmentnaive and IFNb/GA groups.RRs postfingolimod commencement. To determine regardless of whether there was an increase in relapse activity just after fingolimod initiation, RRs through every 3month period in the 15 months preceding fingolimod initiation and inside the 9month period postfingolimod initiation had been determined (figure 1).1272758-17-4 Order Threemonth RRs inside the IFNb/GAfingolimod and naivefingolimod patient groupsTableBaseline patient qualities and relapse activity postfingolimod commence by patient groupAll groups (n 5 536) Naive to fingolimod (n 5 97) 62 (63.9) 30.6 (ten.3) 38.0 (12.2)cIFNb/GA to fingolimod (n 5 350) 255 (72.9) 29.9 (9.8) 40.2 (10.8) eight.7 (four.43.7)c two.5 (1.five)eNatalizumab to fingolimod (n 5 89) 60 (67.4) 29.9 (9.7) 43.two (9.7)cp Value between groups 0.188a 0.826b 0.005b ,0.0001d ,0.0001dFemale, n ( ) Age at MS onset, y, imply (SD) Age at fingolimod commence, y, imply (SD) Disease duration at fingolimod get started, y, median (IQR) EDSS at fingolimod begin, median (IQR) Location, n ( ) Australia Canada Italy Kuwait Spain Other Followup time, patientyears Followup months, median (IQR) Prior treatment duration, y, median (IQR) Sufferers relapsing on fingolimod, n ( ) 1st 3 months 3 months six months Total followup377 (70.3) 30.0 (9.9) 40.three (11.0) 8.6 (four.24.two)4.three (1.7.8)c 1.five (0.five)c12.8 (7.77.two)c four (2)c,e2.5 (1.5.five)304 (56.7) 36 (6.7) 42 (7.eight) 46 (eight.6) 84 (15.7) 24 (four.5) 524.6 ten.three (six.24.9) 44 (45.four) 7 (7.two) 3 (3.1) 14 (14.four) 19 (19.6) ten (ten.3) 167.0 12.three (eight.08.2) c196 (56.0) 26 (7.4) 36 (ten.3) 30 (8.six) 48 (13.7) 14 (4.0) 300.9 ten.0 (6.44.9)c64 (71.9) three (3.4) 3 (three.four) two (two.2) 17 (19.1) 0 (0) 56.7 7.6 (4.22.three)c 2.65 (1.90.26) ,0.0001d2.96 (1.58.66)41 (7.six) 18 (4.four) 16 (5.2) 111 (20.1,4-Dichloro-9,10-anthraquinone uses 7)7 (7.PMID:33733534 two) 1 (1.2) three (4.three) 18 (18.6)c27 (7.7) 12 (four.5) ten (5.0) 75 (21.4)7 (7.9) 5 (9.three)c0.983d 0.01d 0.894d 0.813d3 (7.9) 18 (20.2)Abbreviations: EDSS 5 Expanded Disability Status Scale; GA five glatiramer acetate; IFN five interferon; IQR 5 interquartile range; MS 5 a number of sclerosis. a Pearson x2 test. b Oneway analysis of variance with Bonferroni post hoc test. c Considerable comparisons. d KruskalWallis rank sum test with Bonferroni post hoc test. e Substantial comparisons. 1206 Neurology 82 April 8,FigureRelapse rate by patient group pre and postfingolimod initiationRelapse prices (mean 6 SEM) per 3month interval inside the 15 months preceding fingolimod (FTY) begin and within the 9 months following fingolimod initiation by patient group. This figure demonstrates that the relapse price of individuals switching from natalizumab (NAT) remains comparatively steady on fingolimod, with no shortterm exacerbation of relapse price. Patients switching from interferonb (IFNb)/glatiramer acetate (GA) or who have been p.